Ken Griffin
BDTX icon

Ken Griffin’s Black Diamond Therapeutics BDTX Stock Holding History

Ken Griffin’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$194K Buy
90,900
+38,500
+73% +$91.6K ﹤0.01% 11445
2025
Q4 		$127K Buy
+52,400
New +$186K ﹤0.01% 11451
2025
Q2 		– Sell
-17,000
Closed -$26.4K – 12573
2025
Q1 		$26.4K Buy
17,000
+4,600
+37% +$9.64K ﹤0.01% 12929
2024
Q4 		$26.5K Sell
12,400
-76,000
-86% -$218K ﹤0.01% 12976
2024
Q3 		$385K Buy
88,400
+81,300
+1,145% +$442K ﹤0.01% 8802
2024
Q2 		$33.1K Buy
7,100
+2,100
+42% +$11.3K ﹤0.01% 12165
2024
Q1 		$25.4K Sell
5,000
-100
-2% -$403 ﹤0.01% 12838
2023
Q4 		$14.3K Sell
5,100
-6,600
-56% -$15.5K ﹤0.01% 12883
2023
Q3 		$33.6K Buy
11,700
+7,900
+208% +$29.1K ﹤0.01% 12184
2023
Q2 		$19.2K Buy
3,800
+3,100
+443% +$6.33K ﹤0.01% 12758
2023
Q1 		$1.32K Sell
700
-24,000
-97% -$55.1K ﹤0.01% 14328
2022
Q4 		$44.5K Sell
24,700
-42,600
-63% -$76.7K ﹤0.01% 12277
2022
Q3 		$114K Buy
67,300
+27,700
+70% +$85.4K ﹤0.01% 10978
2022
Q2 		$97K Buy
39,600
+18,200
+85% +$42.3K ﹤0.01% 11436
2022
Q1 		$59K Buy
21,400
+2,700
+14% +$9.86K ﹤0.01% 12694
2021
Q4 		$100K Sell
18,700
-17,700
-49% -$124K ﹤0.01% 12724
2021
Q3 		$308K Sell
36,400
-10,600
-23% -$105K ﹤0.01% 11023
2021
Q2 		$573K Buy
47,000
+31,000
+194% +$613K ﹤0.01% 9748
2021
Q1 		$388K Buy
+16,000
New +$432K ﹤0.01% 10256

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ken Griffin's BDTX Position: Q1 2026 in Review

Ken Griffin increased its Black Diamond Therapeutics (BDTX) stake by 18% in Q1 2026, buying an estimated $184K and bringing the position to 502,652 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #7500.

Ken Griffin first reported a position in BDTX in Q1 2021 and has held it in 18 quarters since. The position peaked at $6.14M in Q2 2023. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Ken Griffin held 502,652 shares of Black Diamond Therapeutics worth $1.07M as of Q1 2026.
  • Ken Griffin bought 77,193 Black Diamond Therapeutics shares in Q1 2026, an estimated $184K.
  • Black Diamond Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #7500 holding.
  • Ken Griffin first reported a position in Black Diamond Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • Ken Griffin's Black Diamond Therapeutics position peaked at $6.14M in Q2 2023.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.